<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Naltrexone</id>
	<title>Naltrexone - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Naltrexone"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Naltrexone&amp;action=history"/>
	<updated>2026-04-17T12:30:22Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Naltrexone&amp;diff=335910&amp;oldid=prev</id>
		<title>Jonrako: /* Mechanism of Action */</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Naltrexone&amp;diff=335910&amp;oldid=prev"/>
		<updated>2022-01-17T05:26:28Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Mechanism of Action&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 05:26, 17 January 2022&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l52&quot;&gt;Line 52:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 52:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Mechanism of Action==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Mechanism of Action==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Opioid &lt;/del&gt;competitive receptor antagonist&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Potent nonselective opioid &lt;/ins&gt;competitive receptor antagonist&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*Reduces the rewarding effects of alcohol consumption  by inhibiting the activity of endogenous opioids in the mesolimbic system. &amp;lt;ref&amp;gt;Anderson, E., Chamberlin, M., Zuluaga, M., Ullal, M., &amp;amp;amp; Hawk, K. (2021). Annals of emergency medicine. Annals of Emergency Medicine, 78(6), 752–758. &amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Comments==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Comments==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Jonrako</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Naltrexone&amp;diff=226831&amp;oldid=prev</id>
		<title>ClaireLewis: Created page with &quot;==Administration== *Type: Opioid antagonist *Dosage Forms: *Routes of Administration: PO, IM *Common Trade Names: ReVia, Vivitrol, Depade  ==Adult Dosing== *Opioid dependence...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Naltrexone&amp;diff=226831&amp;oldid=prev"/>
		<updated>2019-09-01T23:11:18Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Administration== *Type: Opioid antagonist *Dosage Forms: *Routes of Administration: PO, IM *Common Trade Names: ReVia, Vivitrol, Depade  ==Adult Dosing== *Opioid dependence...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Administration==&lt;br /&gt;
*Type: Opioid antagonist&lt;br /&gt;
*Dosage Forms:&lt;br /&gt;
*Routes of Administration: PO, IM&lt;br /&gt;
*Common Trade Names: ReVia, Vivitrol, Depade&lt;br /&gt;
&lt;br /&gt;
==Adult Dosing==&lt;br /&gt;
*Opioid dependence (prevention of relapse after opioid-free x 7-10d), ETOH dependence: 25-50mg PO daily OR 380mg IM q4w&lt;br /&gt;
&lt;br /&gt;
==Pediatric Dosing==&lt;br /&gt;
''Safety/efficacy not established''&lt;br /&gt;
&lt;br /&gt;
==Special Populations==&lt;br /&gt;
===[[Drug pregnancy categories|Pregnancy Rating]]===&lt;br /&gt;
*Category C&lt;br /&gt;
&lt;br /&gt;
===Lactation risk===&lt;br /&gt;
*Minimally excreted in breastmilk&lt;br /&gt;
&lt;br /&gt;
===Renal Dosing===&lt;br /&gt;
*Use caution&lt;br /&gt;
&lt;br /&gt;
===Hepatic Dosing===&lt;br /&gt;
*Use caution&lt;br /&gt;
&lt;br /&gt;
==Contraindications==&lt;br /&gt;
*Allergy to class/drug&lt;br /&gt;
*Patients who are on opioid analgesics/partial agonists, are opioid-dependant, or in acute opioid withdrawal&lt;br /&gt;
&lt;br /&gt;
==Adverse Reactions==&lt;br /&gt;
===Serious===&lt;br /&gt;
*Depression, suicide, and suicidality&lt;br /&gt;
*Vulnerability to opioid overdose: Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after discontinuance of naltrexone&lt;br /&gt;
*Hepatotoxicity&lt;br /&gt;
*Severe injection-site reactions (e.g. necrosis, cellulitis, hematoma)&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Common===&lt;br /&gt;
*Injection site reaction&lt;br /&gt;
*Nausea/vomiting, diarrhea, decreased appetite, dry mouth&lt;br /&gt;
*LFT abnormalities,&lt;br /&gt;
*Elevated CPK&lt;br /&gt;
*Headache, dizziness, anxiety, insomnia, somnolence&lt;br /&gt;
*URI, pharyngitis&lt;br /&gt;
*Arthralgia, muscle cramps, back pain&lt;br /&gt;
*Rash&lt;br /&gt;
&lt;br /&gt;
==Pharmacology==&lt;br /&gt;
*Half-life: PO- 4-13h;IM- 5-10 days&lt;br /&gt;
*Metabolism: Hepatic&lt;br /&gt;
*Excretion: Urinary&lt;br /&gt;
&lt;br /&gt;
==Mechanism of Action==&lt;br /&gt;
* Opioid competitive receptor antagonist&lt;br /&gt;
&lt;br /&gt;
==Comments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
*[[Opioids]]&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:Pharmacology]]&lt;/div&gt;</summary>
		<author><name>ClaireLewis</name></author>
	</entry>
</feed>